

Dr. Alan Lee is a radiation oncologist and Clinical Assistant Professor at UCLA Health in Los Angeles, California.
Podcasts
Vascular & IR # 603Jan 2, 2026Biopsy & Ablation Decision-Making in Lung Cancer

Why might simultaneous ablation and biopsy be the new standard for high-probability lung cancer cases where surgery isn’t an option? In the penultimate episode of the 2025 NSCLC Creator Weekend™ series, our multidisciplinary tumor board panel discusses the intricacies and decision-making processes surrounding biopsy and ablation procedures in thoracic oncology.
Vascular & IR # 599Dec 19, 2025Lung Ablation: Techniques, Challenges & Best Practices

Collaboration between interventional radiology and radiation oncology has enabled high-dose brachytherapy in central lung lesions that were previously untreatable. This episode of the 2025 NSCLC Creator Weekend™ series offers a deep dive into recent advancements in lung ablation and brachytherapy techniques for primary lung cancer.
Vascular & IR # 597Dec 12, 2025Ablative Treatments & Radiotherapy: The Latest in Lung Cancer Treatment

Why might the standard RECIST criteria fail to accurately track success after tumor ablation, and what should you look for instead? In the 4th installment of the 2025 NSCLC Creator Weekend™ series, hosts Drs. Scott Genshaft and Kavi Krishnasamy are joined by specialists from UCLA and USC to discuss and debate advanced treatment options for primary lung cancer.
Tumor Board # 39Dec 9, 2025Biopsy & Ablation Decision-Making in Lung Cancer

Why might simultaneous ablation and biopsy be the new standard for high-probability lung cancer cases where surgery isn’t an option? In the penultimate episode of the 2025 NSCLC Creator Weekend™ series, our multidisciplinary tumor board panel discusses the intricacies and decision-making processes surrounding biopsy and ablation procedures in thoracic oncology.
Tumor Board # 38Dec 2, 2025Lung Ablation: Techniques, Challenges & Best Practices

Collaboration between interventional radiology and radiation oncology has enabled high-dose brachytherapy in central lung lesions that were previously untreatable. This episode of the 2025 NSCLC Creator Weekend™ series offers a deep dive into recent advancements in lung ablation and brachytherapy techniques for primary lung cancer.
Tumor Board # 37Nov 25, 2025Ablative Treatments & Radiotherapy: The Latest in Lung Cancer Treatment

Why might the standard RECIST criteria fail to accurately track success after tumor ablation, and what should you look for instead? In the 4th installment of the 2025 NSCLC Creator Weekend™ series, hosts Drs. Scott Genshaft and Kavi Krishnasamy are joined by specialists from UCLA and USC to discuss and debate advanced treatment options for primary lung cancer.
Vascular & IR # 591Nov 21, 2025NSCLC Tumor Board Discussion: Considerations for Oligometastatic Disease

When cancer spreads to the brain, what is the best approach: immediate local treatment or systemic immunotherapy first? Part two of the 2025 NSCLC Creator Weekend™ series focuses on a complex case involving a 75-year-old woman with a history of breast malignancy, presenting with new dyspnea and a large mass in the left lower lobe.
Vascular & IR # 589Nov 14, 2025Lung Cancer Tumor Boards: Multidisciplinary Approaches & Best Practices

As lung cancer treatments become more complex, is a collaborative tumor board more essential than ever? We’re kicking off the 2025 NSCLC Creator Weekend™ series with an in-studio panel discussion on the multidisciplinary management of lung cancer. The panel includes experts from medical oncology, thoracic surgery, radiation oncology, and interventional pulmonology from major institutions in Los Angeles.
Tumor Board # 35Nov 14, 2025NSCLC Tumor Board Discussion: Considerations for Oligometastatic Disease

When cancer spreads to the brain, what is the best approach: immediate local treatment or systemic immunotherapy first? Part two of the 2025 NSCLC Creator Weekend™ series focuses on a complex case involving a 75-year-old woman with a history of breast malignancy, presenting with new dyspnea and a large mass in the left lower lobe.
Tumor Board # 34Nov 11, 2025Lung Cancer Tumor Boards: Multidisciplinary Approaches & Best Practices

As lung cancer treatments become more complex, is a collaborative tumor board more essential than ever? We’re kicking off the 2025 NSCLC Creator Weekend™ series with an in-studio panel discussion on the multidisciplinary management of lung cancer. The panel includes experts from medical oncology, thoracic surgery, radiation oncology, and interventional pulmonology from major institutions in Los Angeles.